 |
|
|
| |
Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762)
|
| |
| |
Reported by jules Levin
CROI 2013 Atlanta March 3-6
Anton Pozniak,1 Horacio Mingrone,2 Andrey Shuldyakov,3 Carlos Brites,4 Jaime Federico Andrade-Villanueva,5 Debbie Hagins,6 Carlos Beltran Buendia,7 David Dorey,8 Sandy Griffith,9 Sherene Min,9 on behalf of the extended SAILING study team
1Chelsea and Westminster Hospital, London, UK; 2Ciudad Aut—noma de Buenos Aires, Buenos Aires, Argentina; 3Saratov Regional Center of Prophylactic AIDS, Saratov, Russian Federation; 4Complexo Hospitalar Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil; 5Hospital Civil de Guadalajara "Fray Antonio Alcalde," Guadalajara, Jalisco, Mexico; 6Chatham CARE Center, Savannah, GA, USA; 7Hospital Barros Luco Trudeau, Santiago, Chile; 8-9GlaxoSmithKline, 8Mississauga, ON, Canada; 9Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
